Compare Anheuser-Busch Inbev SA (BUD) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Citius Pharmaceuticals Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.97 (market cap $163.79B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Anheuser-Busch Inbev SA is far larger — about 8744.8× Citius Pharmaceuticals Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BUD | CTXR | |
|---|---|---|
Market Cap | $163.79B | $18.73M |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $1.82 |
52-Week Low | $57.93 | $0.48 |
Enterprise Value | $228.20B | $14.95M |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $83.76, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $90.17. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 expected, while revenue trends show modest growth, and net income margin improved to 11.52% in 2025. Cash flow remains positive, and debt-to-asset ratios have declined steadily since 2021.
The outlook is positive given strong analyst buy ratings (57.78%) and projected earnings growth, but risks include competitive pressures and macroeconomic sensitivity. The stock offers value with a P/E of 18.05 and stable profitability, though investor sentiment is mixed amid recent institutional selling and news of a major shareholder divestment.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
